Oncology Central

The aptamer–siRNA conjugates: reprogramming T cells for cancer therapy


Harnessing the body’s own immune system has the potential to generate diverse, yet highly specific antitumor responses with protective long-term effects. Recent clinical advances demonstrated that new cancer immunotherapies can achieve impressive therapeutic effects, even in patients with advanced tumors of various types [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Comments are closed.

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.